| Literature DB >> 33465495 |
Jie Lv1, Lu Ren2, Sensen Han1, Jing Zhang1, Xue Zhao1, Yingna Zhang1, Hua Fang1, Linyuan Zhang1, Haonan Yang1, Shumin Wang1, Junhong Yang3, Xinzheng Cui4, Qingyong Zhang4, Yunke Zhang3, Feng Gao5.
Abstract
In this study, the potential of specific Circular RNAs (circRNAs) as novel peripheral blood biomarkers for myasthenia gravis (MG) was explored. We analyzed circRNAs in the peripheral blood of three normal controls and three MG patients using RNA microarray. Candidate circRNAs were validated in three independent cohorts by Quantitative Real-time polymerase chain reaction (qPCR). Eleven differentially expressed circRNAs were initially identified and four were confirmed in the first independent cohort. Hsa_circ_0076490 and hsa-circ_5333-4 had the largest areas under the curve (AUCs) of the receiver operating characteristics (ROC) and were validated in the second cohort. In the third cohort, hsa-circRNA5333-4 had a larger AUC: 0.864 (95% confidence interval [CI] = 0.801-0.928, P < 0.001), a stronger correlation with the Quantitative Myasthenia Gravis Score (qMG): r = 0.505 (P < 0.001) and was correlated with gender and acetylcholine receptor antibody levels (P < 0.05). So hsa-circRNA5333-4 represents a novel biomarker for the diagnosis and monitoring of MG.Entities:
Keywords: Biomarker; Circular RNA (CircRNA); Hsa-circRNA5333-4; Myasthenia gravis (MG); Peripheral blood
Year: 2021 PMID: 33465495 DOI: 10.1016/j.clim.2021.108676
Source DB: PubMed Journal: Clin Immunol ISSN: 1521-6616 Impact factor: 3.969